In conclusion, our study confirmed that the gut-liver axis was one of the possible ways for SX to improve NAFLD, that is, to regulate the expression of apoB48 and PPARα and protect the intestinal barrier function by changing the relative abundance of gut microbiota, thus reducing the lipid deposition and inflammatory response in the liver. Here, APOB is linked to metabolic dysfunction-associated steatotic liver disease.